The non-steroidal antiandrogens flutamide (Eulexin^®), nilutamide (Anandron^®) and bicalutamide (Casodex^®) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5α-DHT has higher binding affinity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an affinity two to four times higher than 2-hydroxyflutamide, the active metabolite of flutamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhibits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than flutamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival benefits of flutamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival benefits, including those comparing flutamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone. In a direct comparative study, bicalutamide (50 mg, once daily) was compared with flutamide (250 mg, three times daily), each in combination with an LHRH-A. Both therapies were well tolerated, although more patients could not tolerate flutamide therapy: 25 flutamide plus LHRH-A and 2 bicalutamide plus LHRH-A patients withdrew from therapy due to diarrhoea. There were no statistically significant differences for time to progression or survival between the two antiandrogens. This clinical trial of bicalutamide confirms the prediction from preclinical studies that a 50 mg dose of bicalutamide would be appropriate for use in patients with advanced prostate cancer, and demonstrates that this bicalutamide dose is clinically effective when administered as part of CAB.

• Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay

  • Joseph Shaw
  • Mathew Leveridge
  • Davide Gianni

  Scientific Reports (2018)

• Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

  • R Ferraldeschi
  • J Welti
  • J S de Bono

  Oncogene (2015)

• Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer

  • Manoj P. Menon
  • Celestia S. Higano

  Current Oncology Reports (2013)

• Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

  • A Berg
  • A A Dahl
  • S D Fosså

  Prostate Cancer and Prostatic Diseases (2009)

• Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose‐binding site of the human erythrocyte glucose transporter GLUT1

  • Richard J Naftalin
  • Iram Afzal
  • Stuart R Milligan

  British Journal of Pharmacology (2003)